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Abstract
Background: Studies using administrative data report a positive association between ambient air
pollution and the risk of hospitalization for congestive heart failure (HF). Circulating levels of B-
type natriuretic peptide (BNP) are directly associated with cardiac hemodynamics and symptom
severity in patients with HF and, therefore, serves as a marker of functional status. We tested the
hypothesis that BNP levels would be positively associated with short-term changes in ambient
pollution levels among 28 patients with chronic stable HF and impaired systolic function.
Methods: BNP was measured in whole blood at 0, 6, and 12 weeks. We used linear mixed models
to evaluate the association between fine particulate matter (PM2.5), carbon monoxide, sulfur
dioxide, nitrogen dioxide, ozone, and black carbon and log(BNP). Lags of 0 to 3 days were
considered in separate models. We calculated the intraclass correlation coefficient and within-
subject coefficient of variation as measures of reproducibility.
Results: We found no association between any pollutant and measures of BNP at any lag. For
example, a 10 µg/m3 increase in PM2.5 was associated with a 0.8% (95% CI: -16.4, 21.5; p = 0.94)
increase in BNP on the same day. The within-subject coefficient of variation was 45% on the natural
scale and 9% on the log scale.
Conclusion: These results suggest that serial BNP measurements are unlikely to be useful in a
longitudinal study of air pollution-related acute health effects. The magnitude of expected ambient
air pollution health effects appears small in relation to the considerable within-person variability in
BNP levels in this population.
Background
Ambient air pollution is a recognized risk factor for cardi-
ovascular morbidity and mortality [1]. Short-term eleva-
tions in ambient particulate matter have been specifically
implicated in the triggering of acute cardiovascular events
including myocardial infarction [2-4], ventricular arrhyth-
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mias [5-7], and ischemic stroke [8-10]. Several studies
using administrative databases have shown a positive
association between short-term increases in respirable or
fine particles (particulate matter with aerodynamic diam-
eter ≤10 µm (PM10) or ≤2.5 µm (PM2.5), respectively) and
the risk of hospitalization for congestive heart failure (HF)
[11-17]. There is emerging interest in evaluating the
potential health effects of ambient pollution in patients
with chronic stable HF by measuring within-patient
changes in physiologic markers that represent intermedi-
ate endpoints [18], but we are not aware of any published
studies.
Patients with HF who are hospitalized for acute symptom
exacerbations characteristically have elevated cardiac fill-
ing pressures which promote fluid accumulation in the
lungs and/or the peripheral tissues. B-type natriuretic pep-
tide (BNP) is a neurohormone is produced principally by
the ventricles of the heart in response to increasing wall
stress. BNP has beneficial vasodilatory, natriuretic, and
neurohormonal actions which act to reduce this wall
stress [19]. Among patients undergoing treatment for
acute decompensated HF, BNP levels are positively associ-
ated with symptom severity and key indices of cardiac
hemodynamics [20,21], while administration of human
recombinant BNP (Nesiritide) improves both hemody-
namics and symptoms [22]. In patients with chronic sta-
ble HF, circulating levels are positively associated with all
cause mortality [23].
If short-term increases in ambient pollution levels indeed
increase the risk of hospitalization of HF patients for acute
symptom exacerbation, it is plausible that associations
might also be observed with more sensitive markers of
functional status. Because of its favorable properties, BNP
provides a measure of functional status in patients with
HF and offers a potentially attractive opportunity for stud-
ying pollution-related health effects in this patient popu-
lation. The goal of this study was to evaluate the
association between short-term fluctuations in ambient
air pollution concentrations and BNP levels in a panel of
patients with chronic stable HF. To accomplish this, we
carried out a retrospective analysis of a completed clinical
trial in which 3 repeated BNP measurements were made
in study participants over a 3 month period [24].
Methods
This is a retrospective analysis of a completed clinical trial
[24] that randomized 30 patients with HF and impaired
systolic function to receive either 12 weeks of tai chi train-
ing in addition to their usual care, or to usual care alone.
Patients were recruited from outpatient heart failure clin-
ics at Beth Israel Deaconess Medical Center and Brigham
and Women's Hospital in Boston, Massachusetts. Inclu-
sion criteria included left ventricular ejection fraction
≤40% by echocardiography in the past year and mainte-
nance on a stable medical regimen. The intervention con-
sisted of 1-hour group tai chi classes held twice weekly for
12 weeks. Patients currently participating in conventional
cardiac rehabilitation programs were excluded. Addi-
tional methodological details and results have been previ-
ously published [24].
BNP was measured at 0, 6 and 12 weeks from whole
blood collected in ethylenediaminetetraacetic acid using a
fluorescence immunoassay (Biosite Triage BNP Test; San
Diego, California). Patients were followed between Febru-
ary 2002 and March 2003. BNP measurements were miss-
ing on 2 out of 84 (2.4%) visits.
We obtained daily measures of PM2.5 and black carbon
from the Boston/Harvard Countway Library PM Center
which is located <1 km from the study site. To reduce
exposure misclassification, we excluded from analysis 2
patients who lived more than 40 km from this central
monitor. Additionally, we obtained hourly measures of
carbon monoxide (CO), nitrogen dioxide (NO2), sulfur
dioxide (SO2), and ozone from the Massachusetts Depart-
ment of Environmental Protection and calculated daily
average values as previously described [6,7]. We obtained
from the National Weather Service daily summaries of
meteorological data measured at Logan International Air-
port.
We used linear mixed models with random subject-spe-
cific intercepts to evaluate the association between each
pollutant and natural log-transformed BNP concentra-
tions. We modeled each pollutant assuming a linear rela-
tionship and controlled for same day (lag 0) ambient
temperature assuming a quadratic relationship, and mean
ambient temperature over the past 3 days (lags 1–3), same
day dew point, and mean dew point over the past 3 days
assuming linear relationships with the outcome. Indicator
variables for calendar month of blood draw, measure-
ment occasion, treatment assignment, and measurement
occasion by treatment assignment interactions were also
included. PM2.5 levels at lags of 0 to 3 days were consid-
ered in separate models.
To assess the reproducibility of BNP and log(BNP) meas-
urements over the 12 week period, we calculated the
within-subject coefficient of variation (CVWS) and the
intraclass correlation coefficient (ICC) among all subjects
[25]. Variance components were estimated from a mixed
model with random subject intercepts and a fixed effect
for treatment assignment. As a sensitivity analysis, we
repeated this analysis in the control group only. Analyses
were carried out in SAS v9.1 (SAS Institute, Cary, NC). All
p-values are based on two-sided tests at the α = 0.05 level.
This analysis was granted an exemption from institutionalEnvironmental Health 2007, 6:26 http://www.ehjournal.net/content/6/1/26
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review board review by the Beth Israel Deaconess Medical
Center Committee on Clinical Investigations.
Results
Twenty-eight of the 30 patients enrolled in the rand-
omized trial lived ≤40 km from the central monitoring
site and were included in this analysis (Table 1). Subjects
were predominantly male (64.3%) and white (53.6%).
Age at baseline ranged from 33 to 88 years (64.3 ± 13.2;
mean ± SD). Baseline left ventricular ejection fraction
ranged from 10 to 35% (22.5 ± 7.1). BNP levels ranged
from 5.7 to 1300 pg/ml, were log-normally distributed,
and varied considerably within subjects (Fig. 1). Distribu-
tions over the entire study period of pollutant and mete-
orological variables are shown in Table 2. The subject-
specific range (estimated as the difference between sub-
ject-specific maximum and minimum PM2.5 values at lag
0) varied from 0.7 to 50.9 µg/m3 with a mean of 10.9 µg/
m3 and a median of 8.0 µg/m3, suggesting that PM2.5 levels
varied substantially within subjects for the majority of
participants.
PM2.5 levels were not significantly associated with a
change in BNP levels at any of the lags examined. Specifi-
cally, an interquartile range increase (8.1 µg/m3) in
PM2.5 at lags 0, 1, 2, and 3 days was associated with a -
1.5% (95% CI: -18.7, 19.2), 2.1% (-20.0, 30.3), 1.3% (-
12.3, 17.1), 5.6% (-16.8, 34.0) increase in BNP, respec-
tively. No significant associations were observed between
any other pollutant and BNP levels at any of the lags
examined (Fig. 2).
We assessed the reproducibility of measures of BNP on the
natural and log scales (Table 3). On the natural scale
between-subject differences accounted for 85% of the
total variance in measurements of BNP, as determined by
the ICC. Although between-subject differences accounted
for a large portion of the total variance, there was still sub-
stantial within-subject variability (CVWS = 45%). On the
log scale, between-subject differences accounted for 89%
of the total variance, and within-subject variability was
more modest (CVWS = 9.0%). Limiting the analyses to
those subjects in the control group improved the ICC and
CVWS slightly.
Discussion
Air Pollution and Heart Failure
Studies using administrative data have reported a positive
association between short-term increases in ambient par-
ticles and the risk of hospitalization for HF [11-17]. While
the magnitude of the effect is generally small (on the order
of 1% increase in risk for a 10 µg/m3 increase in PM),
these estimates may be biased towards the null by exten-
sive misclassification of both the exposure and the out-
come. To address this problem, Symons et al. [26]
evaluated this association using interview data obtained
from 125 HF patients hospitalized after presenting to the
emergency department and found no association between
any pollutant and risk of symptom exacerbation or hospi-
talization.
However, none of the aforementioned studies have evalu-
ated physiologic markers or intermediate endpoints
repeatedly within subjects as has been extensively done in
BNP concentrations over time in 28 subjects with chronic  stable HF Figure 1
BNP concentrations over time in 28 subjects with 
chronic stable HF. Each line represents repeated measure-
ments from a different subject.
Table 1: Patient characteristics at initial visit (mean ± SD or 
number (%)).
Tai Chi Group (n = 
14)
Control Group (n 
= 14)
Age (years) 66 ± 13 63 ± 14
Male Sex 9 (64) 9 (64)
Race
Black 7 (50) 4 (29)
White 7 (50) 8 (57)
Asian 0 2 (14)
Ejection Fraction (%) 23.7 ± 6.4 21.2 ± 7.9
New York Heart Association Class
I 3 (21) 1 (7)
II 6 (43) 8 (57)
III 3 (21) 5 (36)
IV 2 (14) 0
Heart Failure Etiology
Idiopathic dilated 9 (64) 8 (57)
Ischemic 3 (21) 4 (29)
Hypertensive 0 1 (7)
Alcohol-related 1 (7) 1 (7)
Other 1 (7) 0
Weight (kg) 77.7 ± 19.7 92.2 ± 38.6
BNP (pg/ml) 344 ± 387 304 ± 346Environmental Health 2007, 6:26 http://www.ehjournal.net/content/6/1/26
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other patient populations including healthy elderly and
those with a history of coronary artery disease, diabetes, or
respiratory disease [reviewed by [27]]. Goldberg et al. rec-
ognized this gap in the literature and asked a panel of 31
HF patients aged ≥45 years to maintain a diary of their
weight, blood oxygen saturation, pulse rate, and symp-
toms for 2 months. Preliminary results suggest a very
small but statistically significant inverse association
between ambient particles and blood oxygen saturation
[18], but the final results have not yet been published. In
the current study, we evaluated data from a cohort of
patients with chronic stable HF and we found no evidence
to suggest that short-term increases in ambient air pollut-
ants are associated with changes in functional status as
assessed by circulating levels of BNP.
These findings of very weak or no associations are discon-
certing given the general consistency of the association
between ambient pollution and risk of hospitalization for
HF. One potential reason for the conflicting results is the
heterogeneous clinical presentation and underlying
pathophysiology of patients with HF. This heterogeneity
is captured in the large administrative studies which iden-
tify cases according to discharge diagnoses, but not well
captured in the more selective studies of Goldberg et al.
[18], Symons et al. [26], or the current study where prede-
fined inclusion and exclusion criteria are applied.
Reproducibility of BNP Measurements
We observed that BNP measurements exhibited substan-
tial variability. Although much of this variability was
explained by differences between subjects, there remained
substantial variability in BNP levels within individuals.
There has been considerable interest in evaluating the use
of single measurements of BNP and NT-pro-BNP (an inac-
tive metabolite of pro-BNP) as a diagnostic aid for acute
decompensated heart failure in patients presenting to the
emergency department with acute dyspnea [21,28]. In
contrast, the biologic variability – and hence the useful-
ness of serial BNP measurements in the same individual
over time – has received relatively little attention [29-31].
Although small in size, prior studies have consistently
shown that within-person hour-to-hour and day-to-day
variability in the range of 15 – 30% should be expected in
patients with stable HF. Only the study by Bruins et al.
[30] followed subjects for more than 1 week. These inves-
tigators made repeated BNP measurements over a 6 week
period in 43 patients with HF and found total within-per-
son variability of 41%. This estimate compares favorably
with the estimated CVWS of 45% from the current study.
Association between ambient air pollutants and BNP concen- trations in 28 patients with chronic stable HF Figure 2
Association between ambient air pollutants and BNP 
concentrations in 28 patients with chronic stable HF. 
Results are from single-pollutant mixed models and repre-
sent the increase in BNP levels associated with an interquar-
tile range increase in each pollutant, shown in Table 2.
Table 2: Distribution of pollutants and meteorological variables in the Boston Metropolitan area.a
Variable N Mean SD IQR Correlation with 
PM2.5
PM2.5 (µg/m3) 345 10.9 8.4 8.1 --
Carbon Monoxide 
(ppm)
352 0.44 0.19 0.20 0.35
Sulfur Dioxide (ppb) 352 4.8 3.5 3.4 0.18
Nitrogen Dioxide 
(ppb)
352 20.7 5.9 7.8 0.31
Ozone (ppb) 352 25.1 12.9 15.2 0.35
Black Carbon (µg/m3) 352 0.73 0.45 0.49 0.68
Temperature (°C) 352 11.0 10.2 16.3 0.37
Dew Point (°C) 352 4.2 10.7 16.1 0.38
Barometric Pressure 
(mm Hg)
352 761.4 5.9 7.4 0.05
aDistribution is over the entire study period (February 28, 2002 – February 14, 2003). PM2.5: particulate matter with aerodynamic diameter ≤2.5 
µm; IQR: interquartile range.Environmental Health 2007, 6:26 http://www.ehjournal.net/content/6/1/26
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Arguably, since our analyses of the effects of ambient pol-
lution used log(BNP) as the outcome, CVWS of log(BNP)
values is more relevant. We are not aware of any studies
reporting the CVWS for BNP on the log scale. The CVWS
provides an estimate of the within-subject variability rela-
tive to the mean response, and therefore is dependent on
the measurement scale used. Thus, comparing the CVWS of
BNP on the natural and log scales is not meaningful.
In the context of environmental exposures, these results
imply that an impracticably large sample size would be
required in a repeated-measures study to detect the typi-
cally modest effects of ambient air pollutants that one
might expect to see at the level of an individual subject. In
fact, based on the sample size formulas of Fitzmaurice et
al. [32] and assuming that log(BNP) is modeled, in order
to have 80% power to detect a 5.6% increase in BNP asso-
ciated with an interquartile range increase in PM2.5 (the
largest point estimate for PM2.5 observed in the current
study), a longitudinal study with 5 bi-weekly measures
per subject would require approximately 135 subjects. To
put this effect size into perspective, one large clinical trial
found that 4 months of treatment with the angiotensin
receptor blocker valsartan reduced BNP levels by approxi-
mately 19% in patients with stable HF [33].
Alternative, more direct markers of cardiac function may
perform better. For example, novel Doppler echocardio-
graphic measures have been used in the context of pre-
post studies to demonstrate that cigarette smoking acutely
impairs ventricular relaxation during diastole in healthy
volunteers [34,35]. By extension, serial echocardiography
may provide better insight than BNP levels into the acute
effects of ambient air pollution in patients with HF. How-
ever, the within-subject variability of these measures over
periods of several weeks or months remains largely
unknown.
Strengths and Limitations
Potential limitations of this study include small sample
size, only 3 repeated measures per subject, and an inter-
vention that was shown to significantly lower BNP levels
after 12 weeks. Other potential limitations are worth con-
sidering. First, we were not able to partition total within-
person variability into analytic and biologic variability.
However, for the BNP assay used in this study, the analytic
coefficient of variation is 9–14%, which is small in com-
parison to the biologic variability. Second, we were not
able to evaluate non-environmental sources of biologic
variability such as changes in diet, health status, or medi-
cation usage. It is possible that accounting for these or
other important time-varying factors would significantly
reduce the apparent within-subject variability of BNP.
Finally, this study specifically enrolled patients with HF
and systolic dysfunction. Therefore, the results may not be
generalizable to patients with HF and preserved systolic
function. Strengths of this study include the proximity of
the central site monitor to the study site, a small study
area, and consistency of the measurements. Not with-
standing the above limitations, we are not aware of any
published studies that have assessed the effects of ambient
air pollution on this novel biomarker.
Conclusion
In this retrospective analysis of patients with HF enrolled
in a completed clinical trial, we did not find an associa-
tion between short-term fluctuations in ambient pollut-
ant levels and functional status as assessed by circulating
levels of BNP. Our results suggest that given the high
within-person variability of this novel biomarker, BNP is
unlikely to be a useful endpoint in the context of a
repeated-measures study of the acute health effects of
ambient air pollution.
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Table 3: Reproducibility of BNP and log(BNP) over 12 weeks in patients with chronic stable HF.a
Variance
Number of 
Subjects/Samples
Total Between-Person Within-Person ICC CVWP
BNP
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Only
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14/42 2.53 2.38 0.14 0.94 7.7%
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